Tandem Diabetes Care Inc (TNDM)
Industry Medical Devices
This stock can be held in an Investment ISA and an Investment Account
Sell
$18.40
Buy
$19.17
$-0.20 (-1.06%)
Prices updated at 02 Apr 2026, 21:20 EDT
| Prices minimum 15 mins delay
Prices in USD
Tandem Diabetes Care Inc is a provider of medical care devices in the United States. Its products aid in the delivery of insulin and getting accurate readings through its software application.
Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and
- Key stats
- Price
- Fair value
- Dividends
- News
- Financials
- Valuation
- Profile
Sector
Healthcare
Industry
Medical Devices
Chairman
Ms. Rebecca B. Robertson
CEO
Mr. John F. Sheridan
Most recent earnings
31 Dec 2025
Fiscal year end
31 Dec 2025
Employees
2,500
Head office
12400 High Bluff Drive
San Diego
United States
92130
Key personnel
Owner name | Salary |
|---|---|
Mr. Christopher J. Twomey Independent Director | 0.08m |
Mr. John F. Sheridan Director, President and Chief Executive Officer | 0.73m |
Ms. Peyton R. Howell Independent Director | 0.07m |
Mr. Rajwant S. Sodhi Independent Director | 0.07m |
Ms. Leigh A. Vosseller Executive Vice President, Chief Financial Officer, Treasurer and Principal Accounting Officer | 0.45m |
Ms. Rebecca B. Robertson Chairman of the Board | 0.12m |
Dr. Kathleen McGroddy-Goetz, PhD Independent Director | 0.07m |
Mr. Myoungil Cha Independent Director | 0.06m |
Mr. Joao Paulo Falcao Malagueira Independent Director | 0.06m |
Ms. Sandra Beaver Independent Director | - |
Mr. Rick Carpenter Chief Technical Officer | - |
Ms. Susan Morrison Executive Vice President and Chief Administrative Officer | 0.45m |
Ms. Elizabeth A. Gasser Executive Vice President and Chief Strategy and Product Officer | 0.45m |
Mr. Jean-Claude Kyrillos Executive Vice President and Chief Operating Officer | 0.24m |
Ms. Shannon Marie Hansen Executive Vice President, Chief Legal, Privacy and Compliance Officer and Secretary | - |
Mr. Mark David Novara Executive Vice President and Chief Commercial Officer | 0.45m |
Top 5 shareholders
Owner name | No. of shares |
|---|---|
| BlackRock Inc | 12,101,471 |
| BlackRock Fund Advisors | 7,399,893 |
| Vanguard Group Inc | 7,341,356 |
| Sessa Capital, L.P | 5,000,000 |
| iShares Core S&P Small-Cap ETF | 4,070,675 |
Director dealings
Date | Action |
|---|---|
| 15 Dec 2025 | - |
| 15 Dec 2025 | - |
| 15 Dec 2025 | - |
| 15 Dec 2025 | - |
| 15 Dec 2025 | - |
| 15 Dec 2025 | - |
| 04 Dec 2025 | - |
| 04 Dec 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
| 17 Nov 2025 | - |
Please note that past performance is not a reliable indicator of future returns.